Biosimilar Newsletter Archive

  1. 05.25.17 -- Samsung Bioepis: Biosimilar "Lessons Learned"
    5/25/2017
    05/25/17 Biosimilar Development Newsletter
  2. 05.18.17 -- Behind Samsung Bioepis' 5-Year Rise To Biosimilar Fame
    5/18/2017
    05/18/17 Biosimilar Development Newsletter
  3. 05.11.17 -- 3 Biosimilar Trends In Amgen's 2017 Report
    5/11/2017
    05/11/17 Biosimilar Development Newsletter
  4. 04.27.17 -- Is FDA Taking Too Long On Biosimilars?
    4/27/2017
    04/27/17 Biosimilar Development Newsletter
  5. 04.20.17 -- Why Biosimilar Companies Should Look Inward
    4/20/2017
    04/20/17 Biosimilar Development Newsletter
  6. 04.13.17 -- 6 Predictions About Biosimilars In A Hospital Setting
    4/13/2017
    04/13/17 Biosimilar Development Newsletter
  7. 04.06.17 -- Biosimilars Could Benefit From New Medicare Proposals
    4/6/2017
    04/06/17 Biosimilar Development Newsletter
  8. 03.30.17 -- The 4 Most Notable Biosimilar Interchangeability Hurdles
    3/30/2017
    03/30/17 Biosimilar Development Newsletter
  9. 03.23.17 -- Should Your Biosimilar Really Be A Biobetter?
    3/23/2017
    03/23/17 Biosimilar Development Newsletter
  10. 03.16.17 -- Celltrion: Data Transparency Imperative In 2017
    3/16/2017
    03/16/17 Biosimilar Development Newsletter